Itvisma (onasemnogene abeparvovec-brve) — intrathecal gene therapy coverage criteria
Customize your policy alerts
Sign up for all husky_health policy alerts
Know when husky_health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, prior authorization requirements, and documentation needed for one-time intrathecal administration of Itvisma for members of the Connecticut HUSKY Health (Medicaid) program aged 2 years and older with confirmed 5q SMA.
Itvisma (onasemnogene abeparvovec-brve) is covered as a one-time intrathecal bolus injection for patients age 2 years and older with confirmed SMN1 mutation (5q SMA) when specified criteria are met.
Anti-AAV9 antibody titer requirement: submission of testing demonstrating a titer of < 1:50 is required.
Prior authorization will be valid for 180 days and, if approved, covers a single-dose intrathecal administration only.
Coverage Criteria for Intrathecal Itvisma
Initial Authorization
Itvisma may be considered medically necessary as an intrathecal bolus when ALL of the following are met:
Attach genetic test results
Provider attestation required
Provider attestation required
Submit laboratory results
Provider attestation required
Provider attestation required
Repeat administration of Itvisma (onasemnogene abeparvovec-brve) is considered investigational and not medically necessary.
The policy designates repeat dosing as investigational because the safety and efficacy of repeat administration have not been clinically evaluated. Therefore, subsequent doses beyond the approved one-time intrathecal administration are not covered.
Billing and Coding
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required; single-dose authorization valid 180 days
Prior authorization is required for Itvisma. If approved, the authorization covers a one-time, single-dose intrathecal bolus injection and is valid for 180 days from issuance.
Discontinue other SMA therapies before Itvisma
If the individual is currently receiving other SMA therapy (for example, nusinersen/Spinraza or risdiplam/Evrysdi), that therapy must be discontinued prior to administration of Itvisma and the provider must attest to discontinuation.
Required documentation to accompany prior authorization
Submit a fully completed State of Connecticut Itvisma Prior Authorization Request Form (including physician order and signature) plus supporting clinical documentation as listed below.
- Clinical documentation from treating neurologist including genetic testing confirming 5q SMA
- Baseline labs: liver function tests (AST, ALT, total bilirubin, albumin, PT, PTT, INR), CBC (hemoglobin and platelet count), and creatinine
- Anti-AAV9 antibody titer result demonstrating < 1:50
- Signed provider attestation items (no prior gene therapy, discontinuation of other SMA therapy if applicable, clinical stability, up-to-date vaccinations, corticosteroid regimen per FDA labeling, post‑infusion monitoring of LFTs/CBC/creatinine, anticipated benefit)
- Physician order and signature on the PA form
Triggers for prior authorization denial
Requests may be denied when required documentation or criteria are missing or unmet; common triggers include absence of specialist diagnosis/genetic confirmation, missing anti-AAV9 titer <1:50, missing baseline labs, lack of required provider attestations, or requests for repeat administration.
- No documentation of diagnosis by or consultation with an SMA expert
- No genetic testing confirming 5q SMA
- Anti-AAV9 antibody titer not provided or ≥ 1:50
- Missing baseline liver tests, CBC, or creatinine
- Missing signed provider attestations (e.g., discontinuation of other SMA therapy, monitoring plans)
- Requests for repeat Itvisma administration (repeat dosing considered investigational and not medically necessary)
Clinical Background
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by insufficient survival motor neuron (SMN) protein, resulting in progressive muscle weakness and atrophy; SMA is classified by age of onset (types 0–4). Itvisma is an AAV-based gene therapy (onasemnogene abeparvovec-brve) indicated for treatment of SMA in patients aged 2 years and older with confirmed SMN1 mutation (5q SMA) and is administered as a one-time intrathecal bolus. Patients must be clinically stable and meet preadministration requirements (including genetic confirmation, specialist involvement, baseline laboratory evaluation, and anti-AAV9 antibody testing) prior to receiving therapy.
Definitions and Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.